CAPRICOR THERAPEUTICS, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.7M | $4.0M | $5.5M | $4.8M | $503.2K | $195.5K | $1.4M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $10.8M | $16.0M | $13.8M | $7.8M | $5.2M | $2.6M | $4.1M |
| SG&A Expense | $4.8M | $4.9M | $4.4M | $3.0M | $2.2M | $1.4M | $2.1M |
| Operating Income | $-12.9M | $-17.0M | $-12.6M | $-6.0M | $-6.9M | $-2.1M | $-4.9M |
| Operating Margin | -482.4% | -424.6% | -228.6% | -125.7% | -1,371.7% | -1,074.2% | -361.7% |
| Interest Expense | $398.8K | $344.7K | $248.6K | $200.5K | $58.1K | $0 | $0 |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | $0 | — |
| Net Income | $2.4M | $-18.8M | $-12.9M | $-6.2M | $-8.9M | $-2.1M | $-1.1M |
| Net Margin | 91.2% | -470.3% | -233.0% | -129.9% | -1,767.0% | -1,059.5% | -84.9% |
| EPS (Basic) | $0.03 | $-0.25 | $-0.20 | $-0.13 | $-0.21 | $-0.05 | $-0.03 |
| EPS (Diluted) | $0.02 | $-0.25 | $-0.20 | $-0.13 | $-0.21 | $-0.05 | $-0.03 |
| Shares Outstanding (Basic) | 92.8M | 74.2M | 65.0M | 46.8M | 46.8M | 41.4M | 158.8M |
| Shares Outstanding (Diluted) | 107.2M | 74.2M | 65.0M | 46.8M | 46.8M | 41.4M | 158.8M |
| Dividends Per Share | — | — | — | — | — | — | — |